930 Brittan Avenue
Our mission is to halt neurodegenerative diseases starting with Parkinson’s Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinson’s in human trials within two years, followed by candidates for other neurodegenerative diseases.
AcureX’s approach and founding intellectual property are based on discoveries made by the company’s inventor co-founder, Xinnan Wang MD, Ph.D. Using these insights, AcureX has built a novel mitophagy discovery platform to accelerate drug development and de-risk clinical trials.
The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs.
3 articles with AcureX
AcureX Therapeutics Receives Grant Funding from The Michael J. Fox Foundation For Parkinson’s Research
AcureX Therapeutics Corporation, a privately-held preclinical-stage biopharmaceutical company focused on developing potential disease altering therapeutics for neurodegenerative diseases, announced that it was selected to receive a grant from The Michael J. Fox Foundation to accelerate the development of AcureX’s biomarker for use in Parkinson’s disease drug development and clinical trials.
AcureX Therapeutics Corporation today announced that it was selected to present at the Oppenheimer Biotechnology – Emerging Science Summit on October 15th, 2021.
The Silverstein Foundation for Parkinson’s with GBA today announced grant funding to AcureX Therapeutics to support the development of novel, first in class, small molecule drug candidates for the treatment of Parkinson’s disease (PD).